Skip to main content

Drug Interactions between eliglustat and Opfolda

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between eliglustat and Opfolda. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

eliglustat

A total of 365 drugs are known to interact with eliglustat.

Opfolda

A total of 1 drugs are known to interact with Opfolda.

Drug and food interactions

Major

eliglustat food

Applies to: eliglustat

Do not consume grapefruit or grapefruit juice during treatment with eliglustat unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of eliglustat to dangerous levels. This may increase the risk of serious and potentially life-threatening cardiac side effects such as irregular heart rhythm, heart block, and cardiac arrest. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

migLUstat food

Applies to: Opfolda (miglustat)

Food may delay and/or reduce the absorption of miglustat (brand name Opfolda). This brand of miglustat should be administered on an empty stomach with unsweetened beverages (e.G., water, tea or coffee with no cream, sugar, or sweeteners) at least 2 hours before or 2 hours after food. Other miglustat products (brand names Zavesca and Yargesa) can be taken with or without food. MigLUstat may also cause diarrhea. Talk to your doctor if you are experiencing diarrhea or other digestive problems. Your doctor may suggest a dose adjustment, taking your medication between meals, and/or modifying your diet to have less sucrose, lactose, and other carbohydrates. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Agents for gaucher disease

Therapeutic duplication

The recommended maximum number of medicines in the 'agents for Gaucher disease' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'agents for Gaucher disease' category:

  • eliglustat
  • Opfolda (miglustat)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.